Scinai ImmunotherapeuticsSCNI
About: Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
Employees: 31
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 4 [Q4 2024] → 4 (+0) [Q1 2025]
0% less ownership
Funds ownership: 0% [Q4 2024] → 0% (-0%) [Q1 2025]
47% less capital invested
Capital invested by funds: $85.1K [Q4 2024] → $45.2K (-$39.9K) [Q1 2025]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for SCNI.
Financial journalist opinion









